The purpose of this website is to introduce interested parties to CannoMed (“CannoMed”) so that they can better understand the Company’s activities and expectations. Any and all estimates, assumptions and projections contained in this document are based on information that we believe to be current and correct. This purpose of this document is not to reflect all of the information that may be necessary to comprehensively evaluate the Company.This presentation does not constitute a Due Diligence analysis and does not claim to include all of the information required in order to make an investment decision, nor does it constitute an offer to sell or a solicitation of an offer to purchase. Any information contained within this document is protected and may not be disclosed, reproduced or published, distributed, divulged, modified, transformed, or divided without prior written permission. In- light of the foregoing, you understand and agree that we are not liable nor do we assume any liability for any information contained within this document. In no event shall we be liable for direct, indirect, consequential, special, exemplary, or other damages related to your use of the information contained within this document.
CannoMed is a rising leader in the medical cannabis industry. In the emerging world of medical cannabis production, CannoMed stands out with its unique manufacturing plant which grows and processes cannabis products.
Our indoor facility is a fully controlled and monitored pesticide-free environment with airodroponic growth capabilities, ensuring reproducibility and uniformity in every plant, as well as being entirely indoors, in compliance with German law. The 2700sqm production facility is located in Ziporit Industrial Park in northern Israel.
CannoMed controls all steps of the supply chain, from the indoor growing to the distribution of finished products.
Our technical proficiency and postharvest quality control ensure consistent results, providing clients with a stable and reliable source of produce.
CannoMed offers rising entrepreneurs in the cannabis industry a cooperative opportunity by granting them access to advanced research labs and manpower. Working together allows CannoMed to reach unprecedented results.
CannoMed received all permits and licenses required to grow and produce medical cannabis from the Israeli Ministry of Health.
CannoMed owns a supply agreement with ACA MULLER MEDICAL – a leading German medical, food and cosmetics distributor with official representatives in over 100 countries.
Plant shall be operative in Q4 2020. Indoor growing allows optimal control and monitoring of environmental conditions and prevents pesticides and cross contamination.